Lynx1 Capital Management LP
CIK 1910456
13F filing for Q2 2026・No. 2,819
- Holdings
- US$865.53M
- Quarter change
- +US$232.81M
- Entries
- 27
- Net bought (estimate)
- +US$18.57M
The quarter change is the holdings' value against the quarter before, price moves included — not what was bought or sold; each institution's page estimates that.
Net bought (estimate)
Each stock's change in shares at the quarter-end price, added up: a new position counts as bought, one sold out as sold, shares held long only. Splits are compared split-adjusted; corporate actions under a new CUSIP are not estimated. An estimate from the filings, not actual trades.
- New 6
- Sold out 2
- Cut 7
- Added 6
- Corporate actions 0
- Unchanged 8
Largest holdings
27 stocks worth US$865.53M, options and bonds left out.
| Stock | This quarter | Shares | Value | Weight |
|---|---|---|---|---|
| GH RESEARCH PLCORDINARY SHARES | Added | 13,263,288 | US$356.52M | 41.19% |
| CULLINAN THERAPEUTICS INCCOM | Unchanged | 8,963,500 | US$163.23M | 18.86% |
| STOKE THERAPEUTICS INCCOM | Cut | 4,038,404 | US$132.14M | 15.27% |
| AGIOS PHARMACEUTICALS INCCOM | Added | 3,408,937 | US$126.51M | 14.62% |
| C4 THERAPEUTICS INCCOM STK | Added | 7,326,691 | US$34.22M | 3.95% |
| KORRO BIO INCCOM | Unchanged | 1,538,296 | US$20.27M | 2.34% |
| TSCAN THERAPEUTICS INCCOM | Unchanged | 8,019,148 | US$7.86M | 0.91% |
| PRECISION BIOSCIENCES INCCOM NEW | Cut | 950,466 | US$7.47M | 0.86% |
| NEUPHORIA THERAPEUTICS INCCOM | Unchanged | 875,328 | US$3.83M | 0.44% |
| PASSAGE BIO INCCOM NEW | Added | 673,759 | US$3.29M | 0.38% |
Sign in (free) to see its 27 largest holdings and its trades. Sign in
Filings
The quarter's original 13F filings (SEC).
- 13F-HR/AFiled August 13, 2026SEC ↗
13F covers long positions in US-listed securities only; the data is SEC's, filed within 45 days of the quarter's end.